Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial

Feilin Cao, Zhaosheng Ma, Zenggui Wu, Weizhu Wu, Ouchen Wang, Binbin Cui, Xiaotao Zhu, Jing Hao, Xiaochun Ji, Zhanwen Li, Deyou Tao, Qingjing Feng, Wei Lin, Dongbo Shi, Jingde Shu, Jichun Zhou, Shifen Huang
doi: https://doi.org/10.1101/2024.09.05.24313095

Article usage

Article usage: September 2024 to April 2025

AbstractFullPdf
Sep 20242502854
Oct 202436512
Nov 202423338
Dec 20241181453
Jan 20251112552
Feb 2025481526
Mar 2025422737
Apr 20253211223
Back to top
Posted December 27, 2024.
Download PDF
Data/Code
Email
Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial
Feilin Cao, Zhaosheng Ma, Zenggui Wu, Weizhu Wu, Ouchen Wang, Binbin Cui, Xiaotao Zhu, Jing Hao, Xiaochun Ji, Zhanwen Li, Deyou Tao, Qingjing Feng, Wei Lin, Dongbo Shi, Jingde Shu, Jichun Zhou, Shifen Huang
medRxiv 2024.09.05.24313095; doi: https://doi.org/10.1101/2024.09.05.24313095
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area